PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Nho, K.* ; Kueider-Paisley, A.* ; MahmoudianDehkordi, S.* ; Arnold, M. ; Risacher, S.L.* ; Louie, G.* ; Blach, C.* ; Baillie, R.A.* ; Han, X.* ; Kastenmüller, G. ; Jia, W.* ; Xie, G.* ; Ahmad, S.* ; Hankemeier, T.* ; van Duijn, C.M.* ; Trojanowski, J.Q.* ; Shaw, L.M.* ; Weiner, M.W.* ; Doraiswamy, P.M.* ; Saykin, A.J.* ; Kaddurah-Daouk, R.*

Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers.

Alzheimers Dement. 15, 232-244 (2019)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Introduction: Bile acids (BAs) are the end products of cholesterol metabolism produced by human and gut microbiome co-metabolism. Recent evidence suggests gut microbiota influence pathological features of Alzheimer's disease (AD) including neuroinflammation and amyloid-beta deposition.Method: Serum levels of 20 primary and secondary BA metabolites from the AD Neuroimaging Initiative (n = 1562) were measured using targeted metabolomic profiling. We assessed the association of BAs with the "A/T/N" (amyloid, tau, and neurodegeneration) biomarkers for AD: cerebrospinal fluid (CSF) biomarkers, atrophy (magnetic resonance imaging), and brain glucose metabolism ([F-18]FDG PET).Results: Of 23 BAs and relevant calculated ratios after quality control procedures, three BA signatures were associated with CSFA beta(1-42) ("A") and three with CSF p-tau181 ("T") (corrected P < .05). Furthermore, three, twelve, and fourteen BA signatures were associated with CSF t-tau, glucose metabolism, and atrophy ("N"), respectively (corrected P < .05).Discussion: This is the first study to show serum-based BA metabolites are associated with "A/T/N" AD biomarkers, providing further support for a role of BA pathways in AD pathophysiology. Prospective clinical observations and validation in model systems are needed to assess causality and specific mechanisms underlying this association. (C) 2018 Published by Elsevier Inc. on behalf of the Alzheimer's Association.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
14.423
3.339
65
121
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Metabolomics ; Bile Acid ; Alzheimer's Disease ; Amyloid-beta ; Csf Biomarkers ; Brain Glucose Metabolism ; Pet ; Mri ; Gut-liver-brain Axis; Isolated Rat Hepatocytes; Surface-based Analysis; Gut-brain Axis; Cerebrospinal-fluid; Cholesterol-metabolism; Ursodeoxycholic Acid; Oxidative Stress; Random-field; Vitamin-d; Fdg-pet
Sprache
Veröffentlichungsjahr 2019
Prepublished im Jahr 2018
HGF-Berichtsjahr 2018
ISSN (print) / ISBN 1552-5260
e-ISSN 1552-5279
Zeitschrift Alzheimer's & Dementia
Quellenangaben Band: 15, Heft: 2, Seiten: 232-244 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort New York, NY [u.a.]
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Bioinformatics and Systems Biology (IBIS)
POF Topic(s) 30505 - New Technologies for Biomedical Discoveries
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-503700-001
DOI 10.1016/j.jalz.2018.08.012
WOS ID WOS:000457693500005
Scopus ID 85060999700
PubMed ID 30337152
Erfassungsdatum 2018-10-25
[➜Korrektur melden]